| Filed On | Filing |
|---|---|
| 12 Nov 2026 |
8-K: Results of Operations and Financial Condition
Initiated Phase 1 study of AP03, a fixed dose combination of nebulized pirfenidone and nintedanib, in healthy volunteers |
| 16 Sep 2026 |
8-K: Departure/Election of Directors or Officers; Compensation
On September 15, 2026 (the “Effective Date”), upon the recommendation of the Nominating and Corporate Governance Committee of the Board of Directors (the “Board”) of Avalyn Pharma Inc. (the “Company”), the Board appointed Robert Meyer, M... |
| 12 Aug 2026 |
8-K: Results of Operations and Financial Condition
Completed enrollment of MIST global Phase 2b trial of AP01 with 398 patients; topline data expected in the second half of 2027 |
| 01 Jul 2026 |
8-K: Entry into a Material Definitive Agreement
THIS FIRST AMENDMENT TO SUBLEASE (this “Amendment”) is made and entered into as of June 29, 2026 (the “Effective Date”), by and between CRISPR THERAPEUTICS, INC., a Delaware corporation, with a place of business at 105 West First Street,... |
| 17 Jun 2026 |
8-K: Regulation FD Disclosure
Avalyn Completes Target Enrollment in Phase 2b MIST Trial of AP01 (Inhaled Pirfenidone) for Patients with Progressive Pulmonary Fibrosis |
| 03 Jun 2026 |
8-K: Results of Operations and Financial Condition
On track to complete enrollment of MIST Phase 2b trial of AP01 in progressive pulmonary fibrosis (PPF) in mid-2026, with newly presented long term open-label extension clinical data that support favorable tolerability profile |
| 01 May 2026 |
8-K: Amendments to Articles/Bylaws; Change in Fiscal Year
SECTION 1. Annual Meeting. The annual meeting of stockholders (any such meeting being referred to in these Bylaws as an “Annual Meeting”) shall be held at the hour, date and place within or without the United States that is fixed by or i... |
Loading...